Search results
Showing 951 to 1000 of 1305 results for long term conditions
This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)
Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.
This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS38Show all sections
Sections for QS38
- Quality statements
- Quality statement 1: Risk assessment
- Quality statement 2: Immediate endoscopy for people who are haemodynamically unstable
- Quality statement 3: Endoscopy within 24 hours for people who are haemodynamically stable
- Quality statement 4: Endoscopic treatment for non-variceal bleeding
- Quality statement 5: Treatment of non-variceal bleeding after first or failed endoscopic treatment
- Quality statement 6: Prophylactic antibiotic therapy for variceal bleeding
- Quality statement 7: Band ligation for oesophageal variceal bleeding
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
dorsal rhizotomy suggests that the procedure results in some short- and medium-term improvements in motor function. The effects reported...
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)
Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.
Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)
NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Photodynamic therapy for localised inoperable endobronchial cancer (HTG85)
Evidence-based recommendations on photodynamic therapy (PDT) for localised inoperable endobronchial cancer (non-small-cell lung cancer). This involves injecting a photosensitising agent into the body that is activated by laser light to destroy the cancerous tissue.
View recommendations for HTG85Show all sections
Sections for HTG85
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs
Curos for preventing infections when using needleless connectors (HTG510)
Evidence-based recommendations on Curos for preventing infections when using needleless connectors.
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.
Read the biographies of our medical technologies advisory committee members.
Read the biographies of our medical technologies advisory committee members.
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.
This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Learning disability: identifying and managing mental health problems (QS142)
This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.
View quality statements for QS142Show all sections
Sections for QS142
- Quality statements
- Quality statement 1: Annual health check
- Quality statement 2: Assessment by a professional with relevant expertise
- Quality statement 3: Key worker
- Quality statement 4: Tailoring psychological interventions
- Quality statement 5: Annually documenting the reasons for continuing antipsychotic drugs
- Update information
- About this quality standard
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.
This guideline covers promoting physical activity for children and young people aged under 18 at home, preschool, school and in the community. It includes raising awareness of the benefits of physical activity, listening to what children and young people want, planning and providing spaces and facilities, and helping families build physical activity into their daily lives.
Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)
NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Danis stent for acute oesophageal variceal bleeding (HTG574)
Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding.
NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
Axonics sacral neuromodulation system for faecal incontinence (MIB259)
NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.